Proteomics of Endometrial Cancer Diagnosis, Treatment, and Prognosis
Overview
Authors
Affiliations
This review discusses the current status of proteomics technology in endometrial cancer diagnosis, treatment and prognosis. The first part of this review focuses on recently identified biomarkers for endometrial cancer, their importance in clinical use as well as the proteomic methods used in their discovery. The second part highlights some of the emerging mass spectrometry based proteomic technologies that promise to contribute to a better understanding of endometrial cancer by comparing the abundance of hundreds or thousands of proteins simultaneously.
Akkour K, Alanazi I, Alfadda A, Masood A, Alhalal H, Joy S BMC Cancer. 2024; 24(1):752.
PMID: 38902713 PMC: 11191338. DOI: 10.1186/s12885-024-12522-0.
Taylor A, Konje J, Ayakannu T Cancers (Basel). 2023; 15(18).
PMID: 37760635 PMC: 10527058. DOI: 10.3390/cancers15184665.
Dellino M, Cerbone M, Lagana A, Vitagliano A, Vimercati A, Marinaccio M Int J Mol Sci. 2023; 24(11).
PMID: 37298731 PMC: 10253366. DOI: 10.3390/ijms24119780.
Chen Y, Yao Q, Zeng X, Hao C, Li X, Zhang L Front Oncol. 2022; 12:1014159.
PMID: 36408150 PMC: 9671074. DOI: 10.3389/fonc.2022.1014159.
Mittal P, Condina M, Klingler-Hoffmann M, Kaur G, Oehler M, Sieber O Cancers (Basel). 2021; 13(21).
PMID: 34771551 PMC: 8582378. DOI: 10.3390/cancers13215388.